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Objectives: The universal response of vein grafts after insertion into the arterial circulation is the development of intimal 
hyperplasia; smooth muscle cell proliferation and connective tissue deposition, which may be modulated in part by 
dysfunctional endothelial nitric oxide (NO) metabolism. This study examines the effects of single dose, local application 
by pluronic gel of a NO donor, S-nitroso-N-acetylpenicillamine (SNAP) and an NO synthase inhibitor nitro-L-arginine 
methyl ester (L-NAME) on the formation of intimaI hyperplasia. 
Materials: Forty New Zealand white rabbits underwent jugular vein interposition grafting of the common carotid artery. 
Design: Ten animals were controls, 10 animals had the outer surface of the vein graft coated with 30% pluronic gel 
(2.5 ml), and 10 each were immersed for 15 rain prior to insertion in Ringer lactate containing 10=3M of SNAP ot" L- 
NAME and then had their vein grafts coated with 2.5 mI of gel containing either SNAP (10-3M) or L-NAME (104M), 
which allows for sustained elivery for up to 6 h. On the 28th post operative day, the animals were sacrificed and 
vein grafts were harvested for morphology by electron microscopy (SEM and TEM) and dimensional analysis by 
videomorphometry. 
Results: All vein grafts developed intimal hyperplasia. On SEM the vein grafts had a confluent layer of endothelial cells 
with multiple layers of smooth muscle cells representing intimal hyperplasia in TEM. There were no demonstrable 
morphological differences between the four groups. Local treatment with SNAP produced a significant 36% decrease in 
mean intimal thickness (72 + 4 #m vs. 45 +_ 4 #m; mean ± S.E.M.; p<O.01) without a change in medial thickness compared 
to gel-only treated groups (58 ± 6 #m vs. 61 ± 7 #m; p = ns). h~hibition of NO synthase by L-NAME had no effect on 
the development of intimal hyperplasia (72 ±4 #m vs. 79 ± 10 #m; p = ns); medial thickness was also unchanged. 
Conclusion:" These data confirm the protective ffect of NO in vascular injury and suggest hat NO synthase activity is 
either absent or reduced to such a level that further inhibition in this short time course is not relevant o the pathophysiologa d 
of vein graft intimaI hyperplasia. 
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Introduction 
Intimal hyperplasia is a common phenomenon oc- 
curring in arterial vein bypass grafts and is considered 
a universal response to insertion of a vein into the 
arterial circulation. Focal development of intimal hy- 
perplasia is responsible for early stenosis in over 30% 
of peripheral vein grafts within 1 year and accounts 
for 20-40% of graft failures within the first 5 years. ~-3 
The pathogenesis of intimal hyperplasia is a complex 
interaction of physical, cellular (platelets and leuko- 
cytes) and humoral  factors. 4 Loss of endothelium de- 
pendent nitric oxide (NO)-mediated relaxation due to 
* Presented at the 10th Annual Meeting of the European Society for 
Vascular Surgery, Venice, Italy; September 1996. 
~-Please address all correspondence to: P-O. Hagen. 
the physical loss of the endothelial ining or an 
acquired dysfunction of the endothelial cells is char- 
acteristic of intimal hyperplastic lesions. 5Production 
of NO can inhibit platelet aggregation and inhibit 
leukocyte adhesion, function and chemotaxis. 6 Fur- 
thermore, NO can directly inhibit smooth muscle cell 
growth.6 sThe relationship of endothelial cell structure 
and function to the development ofintimal hyperplasia 
is well recognised. 4'9 Usually, vascular smooth muscle 
cells exist in a quiescent state which is modulated by 
the overlying endothelium. With the loss of normal 
endothelial cell function, smooth muscle cell pro- 
liferation occurs, and even with the restoration of 
normal endothelial cell coverage, the abnormal smooth 
muscle cell growth takes longer to return to a homeo- 
static state. ~° 
Production of free radicals and degradation of nitric 
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oxide are part of the same spectrum. 11NO may be 
considered a free radical scavenger and thus a cyto- 
protective factor. 12'13 NO can also be converted to per- 
oxynitrite, a potent cellular toxin. ~4 In addition, NO 
synthases can also produce oxygen free radicals if L- 
arginine levels are  low.  15"16 Thus, interference in the 
production of free radicals or increasing the avail- 
ability of NO should be beneficial in reducing intimal 
hyperplasia. We have previously demonstrated that 
single dose local application of a free radical scavenger, 
desferrioxamine manganese, reduces intimal hyper- 
plasia. 17 There is presently no information on the role 
of a single application of a NO donor or inhibition of 
NO synthase on the development ofvein graft intimal 
hyperplasia. This study examines the effects of single 
dose, local application by pluronic gel of a NO donor, 
S-nitroso-N-acetylpenicillamine (SNAP), and a NO 
synthase inhibitor, nitro-L-arginine methyl ester (L- 
NAME), on the formation of intimal hyperplasia. 
Material and Methods 
Forty New Zealand white rabbits weighing 2.0-2.5 kg 
underwent right common carotid artery bypass graft- 
ing using the ipsilateral external jugular veins as pre- 
viously described, is Ten animals were controls, 10 
animals had the outer surface of the vein graft coated 
with 30% pluronic gel (2.5 ml F127 Pluronic gel, BASE 
Washington, NJ), and 10 each were immersed for 
15 min prior to insertion in Ringer lactate containing 
10-3 M of S-nitroso-N-acetylpenicillamine (SNAP) and 
an NO synthase inhibitor nitro-L-arginine methyl ester 
(L-NAME) and then had their vein grafts coated with 
2.5 ml of gel containing either SNAP (10-3M) or L- 
NAME (10-3M) which allows for sustained elivery 
for up to 6h. On the 28th postoperative day, the 
animals were sacrificed and vein grafts were harvested 
for morphology by electron microscopy (SEM and 
TEM), dimensional analysis by videomorphometry 
and isometric tension studies. All animals were sac- 
rificed with an overdose of barbiturates 28 days after 
the operation. Animal care complied with the "Prin- 
ciples of Laboratory Animal Care" as formulated by 
the National Society for Medical Research and the 
"Guide for the Care and Use of Laboratory Animals" 
issued by the National Institutes of Health. (U.S. 
Department of Health and Human Services, NIH 
Publication No. 80-23, revised 1985.) 
Morphological studies 
Following isolation and heparinisation (200 IU/kg, 
i.v.), six control and six experimental grafts were per- 
fusion fixed in situ at 80 mmHg with a standardised 
initial infusion of Hanks Balanced Salt Solution (HBSS, 
Gibco Laboratories, Life Technologies Inc., Grand 
Island, NY) followed by 2% glutaraldehyde made up 
in 0.1 M cacodylate buffer (pH 7.2) supplemented with 
0.1 M sucrose to give an osmolality of approximately 
300 mOsm. After immersion in the fixative for 48 h, 
cross-sections from the middle-third of the graft were 
processed and stained with a modified Masson's tri- 
chrome and Verhoeff's elastin stain. The lumen, intima 
and the media were defined and their dimensions (area 
and/or thickness) calculated by videomorphometry 
(Innovision 150, American Innovision Inc., San Diego, 
CA). A ratio of the intimal and medial areas (intimal 
ratio -- intimal area/intimal+medial reas) and a 
luminal diameter to cross-sectional wall thickness 
(luminal index =luminal diameter/cross-sectional 
wall thickness) were calculated. For scanning electron 
microscopy (SEM), mid portion specimens of the glu- 
taraldehyde-fixed grafts were rinsed with the same 
buffer solution as described above, dehydrated in 
ascending concentrations of ethanol, transferred to 
absolute acetone, critical point dried from CO2, moun- 
ted on specimen stubs and sputter-coated with gold- 
palladium according to standard techniques. All speci- 
mens were examined in a Philips 500 scanning electron 
microscope (N.V. Philips, Eindhoven, The Nether- 
lands) at an accelerating voltage of 12 or 20 kV. For 
transmission electronmicroscopy (TEM), represent- 
ative sections from the mid-portion of the glutar- 
aldehyde-fixed grafts were post-fixed for i h at room 
temperature in 1% osmium tetroxide dissolved in the 
same cacodylate buffer as used for the glutaraldehyde 
solution. After dehydration in ascending con- 
centrations of ethanol, the specimens were transferred 
to propylene oxide and finally embedded in Epon 812 
monomer. Polymerisation was carried out overnight 
at 40 °C followed by 2 days at 60 °C. Ultrathin sections 
were cut with a diamond knife on a Reichart ultra- 
microtome (Reichart Optische Werke AG, Vienna, Aus- 
tria), contrasted with uranyl acetate and lead citrate, 
and then examined in a Philips 300 transmission elec- 
tron microscope (N.V. Philips, Eindhoven, The Neth- 
erlands) both operated on at 60 kV. 
Physiological studies 
For isometric tension studies, vessels were sectioned 
in situ into four 5 mm segments, excised and each ring 
was immediately mounted between two stainless teel 
hooks in 5 ml organ baths containing oxygenated Krebs 
solution (122 mM NaC1, 4.7 mM KC1, 1.2 mM MgC12, 
215 mM CaC12, 15.4 mM NaHCO3, 1.2 mM KH2PO4 and 
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5.5 mM glucose, maintained at 37 °C and oxygenated 
with 95% 02 and 5% CO2) as previously described. 18
Following equilibration, the resting tension was 
adjusted in increments from 0.5 to 2.5 gms and the 
maximal response to a modified oxygenated Krebs 
solution containing 60 mM KC1, 66.7 mM NaC1, 1.2 mM 
MgC12, 2.5raM CaCI2, 15.4mM NaHCO3, 1.2raM 
KH2PO4 and 5.5 mM glucose was measured to establish 
a length-tension relationship. Cumulative dose re- 
sponse curves to norepinephrine (10-9-10-4M), brady- 
kinin (10-9-10-5M) and serotonin (10-9-10 4M) were 
performed. After precontraction with norepinephrine 
(concentration that produces 75% maximal con- 
traction), relaxation in response to acetylcholine 
(10-8-10 .4 M) and sodium nitroprusside (10-8-10-4M) 
was determined. The tissue was allowed to re-equi- 
librate for a minimum of 30 rain between each ex- 
perimental run. All drugs were obtained from Sigma 
Chemical Co. (St Louis, MO). 
In vitro DNA, protein and collagen synthesis and cell 
proliferation studies 
Vascular smooth muscle cells from the media of the 
thoracic aorta of male New Zealand white rabbits were 
isolated and grown in tissue culture as previously 
described. Cells in the sixth through ninth passages 
were used for these experiments. Confluent cells in 
75 cm 2 culture flasks (Falcon Plastics, Lincoln Park, 
NJ) were washed twice with 8 ml phosphate buffered 
saline (Gibco Laboratories, Grand Island, NY) followed 
by trypsinization for 7 min at 37 °C with 8 ml trypsin/ 
EDTA solution (Gibco). Three ml of Dulbecco's min- 
imal essential medium (Gibco) with 10% foetal calf 
serum (Gibco) was then added to inactivate the trypsin. 
The cells were isolated by centrifugation (250 g for 10 
min) and resuspended in Dulbecco's minimal essential 
medium with 10% foetal calf serum (growth medium, 
Gibco) containing penicillin (100 IU/ml), streptomycin 
(100 ~tg/ml) and amphotericin B (125 ~g/ml). 
H 3 Thymidine incorporation 
Culture wells (six-well cluster dishes, 35 mm diameter; 
Falcon Plastics) were inoculated with 3 ml growth 
medium containing 5x 104 cells. The growth medium 
was replaced with new medium every third day until 
the cells reached confluency as judged by microscopic 
examination. The cells grew in hills and valleys typical 
of vascular smooth muscle cells. On reaching con- 
fluency, the medium was not changed for 3 days to 
induce a quiescent state in the cells. On the day of the 
experiment, new growth medium was exchanged 3 h 
before the initiation of the experiment. The ex- 
periments were initiated by exchanging the growth 
medium with new medium containing 4 ~tCi [H3]  - 
thymidine (2 Ci/mM: ICN, Irvine, CA) with and with- 
out S-nitroso-N-acetylpenicillamine or nitro-L-ar- 
ginine methyl ester from concentration of 10-8M to 
10 -2 M. Incorporation of H3-thymidine into acid-pre- 
cipitable material was measured after a 24 h incubation 
period (air plus 5% CO2 at 37 °C). At harvest, the 
dishes were placed on ice and each well was washed 
twice with 3 ml of ice cold Dulbecco's phosphate- 
buffered saline (Gibco). Three ml ice cold 5% tri- 
chloracetic acid were added. After 15 min, the acid 
was removed and each well washed with 4 ml ice cold 
water. Sodium hydroxide (1 ml, 0.2 N) was then added 
and the dishes were incubated for 20 rain at 37 °C. 
Aliquots (100 gl) of the sodium hydroxide solution 
were counted in 10 ml Lefko-fluor (Research Products 
International Corp., Mount Prospect, IL) by a Packard 
Tri-carb 4530 scintillation counter (Packard In- 
struments Inc., Downers Grove, IL). Results are ex- 
pressed as percentage of control. 
Cell proliferation 
Culture wells (six-well cluster dishes, Falcon) were 
inoculated with 3ml growth medium containing 
5 × 10 4 cells and allowed to attach over night. Cell 
proliferation was assessed in the absence of and in 
the presence of five concentrations of S-nitroso-N- 
acetylpenicillamine (10 _5 M, 5 x 10 .5 M, 10 4 M, 
5 × 10 -4 M, 10 _3 M) or four concentrations of nitro-L- 
arginine methyl ester (5 x 10-4M, 10 -3 M, 5 × 10-3M, 
10-2M). Each compound was added to the culture 
media from the second day. Cell counts were de- 
termined on days 1, 2, 3, 4, 5, 6, 8 and 12. Cells from 
each well were removed by trypsinisation and then 
microscopically counted using a blood cell haem- 
ocytometer (Improved Neubauer Haemacytometer, 
0.1 mm deep, AO, Buffalo, NY). There were three wells 
for each group per day and for each well, two cell 
counts were averaged and only accepted as accurate 
if the counts were within 10% of each other. The cell 
counts were then averaged to produce the mean cell 
count for each experimental group for each day. 
Total protein and collagen synthesis 
Culture wells (six-well cluster dishes, Falcon) were 
inoculated with 3 ml growth media containing 5 x 10  4 
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cells and allowed to reach confluency. To achieve 
quiescence, the cells were washed three times with 
serum-free media and cultured for 2 days in media 
lacking FCS but supplemented with 0.5% bovine al- 
bumen. Cells were then cultured for 24 h in media 
supplemented with 10% FCS and containing SNAP 
(0.0 M, 0.4 raM, 0.8 mM and 1.2 raM) or cycloheximide 
(1 gM). L-2,3,4,5-H 3 proline (114 Ci/mmol, 2 btCi/ml 
of medium; Dupont, Boston, MA) or L-4,5-H a leucine 
(47.5 Ci/mmol, 10 btCi/ml of medium; Dupont, Boston, 
MA) were added for the last 2 h of incubation (air 
plus 5% CO2 at 37 °C). After incubation with SNAP 
or cycloheximide, the relative rate of total protein 
synthesis in the smooth muscle cells was measured 
as H 3 leucine incorporation into trichloracetic acid 
precipated material} 9 To determine the relative rate of 
collagen synthesis, culture medium was removed and 
added (vol/vol) to cold buffer (pH 7.4) containing 
0.65 M NaC1, 4.7raM CaC12, 0.1 M Tris, 2.5 mg/ml N- 
ethylmaleimide. 2° Bovine serum albumen (100 btg/ml) 
was added as a carrier. Two aliquots from each sample 
were examined: one aliquot was digested with col- 
lagenase III (10 U/ml  medium) for 90 min at 37 °C and 
one aliquot was the undigested control. Total protein 
and collagen synthesis in the smooth muscle cells was 
measured as (H 3) proline incorporation into tri- 
chloracetic acid precipated material from both 
samples. The relative rate of collagen synthesis was 
determined based on the assumption that the ratio of 
proline residues in collagen relative to non-collagen is
5:4. Each aliquot (100 gl) was counted in 10 ml Lefko- 
fluor by a Packard Tri-carb 4530 scintillation counter. 
Results are expressed as percentage of control. 
Data and statistical analysis 
The ECso value, the concentration for the half maximal 
response, for each agonist in each ring was calculated 
by logistic analysis and is expressed as the pD2 which 
is defined as -lOglo(ECso)ak gmax (the maximal response 
expressed as a ratio of the contraction to 60 mM KC1) 
was also calculated. All data are presented as the 
mean+standard error of the mean (S.E.M.) and stat- 
istical differences between groups were tested by 
ANOVA with post hoc Tukey-Kramer multiple com- 
parison tests for the functional studies and with a 
Kruskal-Wallis non-parametric ANOVA with post hoc 
Dunn's multiple comparison tests for the mor- 
phometric data. A p value less than 0.05 is regarded 
as significant. 
Fig. 1. A composite photomicrograph s owing a cross-section from 
the wall of the middle segment of a control (A), gel coated (B), 
L-NAME (C) and SNAP (D)-treated vein grafts. H=int imal 
hyperplasia, M = media. Arrows indicate the demarcation between 
the intima and media. Dimensions are shown in Table 1. Mag- 
nification x 100. 
Results 
General 
All animals survived to harvest. There were no graft 
occlusions. No in vivo toxic effects of SNAP or L-NAME 
were noted. At harvest, there were no macroscopic 
differences between the control, gel, SNAP or L-NAME 
treated vein grafts. In light microscopy, the intimal 
hyperplasia on the control and experimental groups 
of vein grafts were similar, although the degree of 
intimal hyperplasia in the SNAP treated vein grafts 
was much less (Fig. 1). 
Morphology 
Application of the pluronic gel to the external surface 
of the vein grafts did not result in a change in the 
intimal thickness (72 +4 ~tm, p =ns) or medial thick- 
nesses (68 + 6 ~tm, p = ns).Local treatment with SNAP 
produced a significant 36% decrease in mean intimal 
thickness (72+4~tm vs. 45_+4~tm; mean+s.mM. 
p<0.01) without a change in medial thickness com- 
pared to controls or gel only treated groups (58 + 6 ~tm 
vs. 61 _+ 7 ~tm; p =ns). Inhibition of NO synthase by L- 
NAME had no effect on the development of intimal 
hyperplasia (72 + 4 ~tm vs. 79 + 10 txm; p = ns)compared 
to gel coated controls. The intimal ratio of the SNAP 
treated vein grafts decreased by 32% compared to the 
gel coated control (Table 1). There was only a 4% 
increase in overall luminal area of the SNAP treated 
vein grafts compared to gel coated controls (28.1 + 3.4 
vs. 26.9 _+ 2.8 mm2; p = ns). The luminal index, a meas- 
ure of changes in luminal diameter in relation to total 
wall thickness, increased by 35% with SNAP therapy 
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Table 1. Dimensional analysis. 
Control (n = 6) Gel control (n = 6) SNAP (n = 6) L-NAME (n = 6) p-value 
Lumen (mm 2) 13.9--2 26.9_+2.8* 28.2_+3.4* 24.6-t-2.9 0.005 
Intima (ram 2) 0.98 + 0.11 1.38 ± 0.11 0.83 ,1, 0.08~-:~ 1.42 ± 0.23 0.02 
Media (mm 2) 0.97 '1' 0.07 1.14 -- 0.09 1.36 ±0.09 1.49 -t-0.37 0.28 
Intimal ratio 0.49 ,1, 0.03 0.54 ,1, 0.03 0.41,1, 0.03*f~ 0.53 + 0.05 0.01 
Luminal index 29.6 ,1, 3.1 44.1,1, 3.1 59.4 '1' 7.7"*:~ 38.9 ,1, 4.4 0.003 
The area of the lumen, the intimal andthe medial layers from the control, gel encased nd S-nitroso-N-acetylpenicillamine (SNAP) and 
nitro-L-arginine methyl ester (L-NAME) treated grafts. The intima ratio (intimal area/(intimal + medial areas) and luminal index (luminal 
diameter/(cross-sectional wall thickness) are also shown. Values are the mean-t-S.E.M. Statistical differences between groups were te ted 
by Kruskal-Wallis non-parametric ANOVA with post hoc Dunn's multiple comparison tests (*p<0.5 and **p<0.01 vs. control, t p<0.05 vs. 
gel control, :~ p<0.05 vs. L-NAME). 
Fig. 2. (a) Scanning electron micrograph of the endothelial lining of a SNAP-treated vein graft showing well defined endothelial cells (E) 
with sharp cell borders (arrowheads). There is no disruption of the endothelial lining. The white dots at the cell bodies represent small 
villi-like plasma membrane projections. Magnification x 1250. 
(b) Scanning electron micrograph of a L-NAME-treated vein graft showing intact sharply outlined endothelial cells. Numerous tomata 
of the cell juntions are seen (arrowheads). Magnification × 1250. 
(Table 1). L-NAME therapy resulted in no significant 
changes in intimal ratio, luminal area or luminal index 
(Table 1). 
The ultrastructural characteristics of the endothelial 
surfaces were examined in the scanning electron micro- 
scope° Control vein graft and gel coated vein graft 
were covered by continuous layers of endothelial cells 
which had distinct cell borders and were covered by 
numerous minute surface processes. Both the SNAP 
and L-NAME treated vein graft (Figs 2a and 2b) 
showed well defined endothelial cells with sharp cell 
borders like those of the gel and control vein grafts. In 
contrast, the L-NAME treated vein graft had numerous 
stomata at the cell junctions (Fig. 2b). Transmission 
electron microscopy of the control and gel coated vein 
grafts showed a well defined monolayer of endothelial 
cells. Beneath the endothelium, the wall of all vein 
grafts were composed of multiple layers of smooth 
muscle cells embedded in a matrix of poorly developed 
connective tissue. The smooth muscle cells were both 
of the synthetic (i.e. the cytoplasm containing a large 
fraction of synthetic organelles) and the contractile (i.e. 
the cytoplasm is predominant ly occupied with well 
organised myofi laments) phenotypes. In the intimal 
hyperplasia little well defined collagen was found. 
Collagen was, however, prominent in the media and 
in the advent±fla. In TEM of the SNAP treated vein 
grafts, the endothelial cells appeared similar to the 
control and gel treated vein grafts, beneath which 
were multiple layers of slender smooth muscle cells 
of the contractile phenotype (Figs 3a and 3b). The 
intercellular spaces between the smooth muscle cell 
were filled with disorganised connective tissue. In 
the L-NAME treated vein grafts, the ndothelial cells 
appeared similar to the control, gel treated and SNAP 
treated vein grafts in TEM. However,  in contrast o 
the SNAP treated vein grafts, the smooth muscle cells 
in the intimal hyperplasia ppeared predominately to
be of a synthetic phenotype (Figs 3a and 3b) in the L- 
NAME treated vein grafts. The appearance of the 
intercellular connective tissue was similar in both treat- 
ment groups. 
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Fig. 3. (a) Transmission electron mmrograph of  SNAP-treated vein graft showing unaltered well preserved endothelial cells (E). 
Endothelial cell junctions are indicated by the arrowhead. Beneath the endothelium slender smooth muscle cells are noted (S). There is 
poor development of the rough endoplasmic reticulum in these cells with an increase in contractile filaments (arrow). The space between 
the smooth muscle cellis voluminous with some flocculent material (asterisks). Original magnification x 3000. 
(b) Transmission electron micrograph of a the same SNAP-treated vein graft as shown in (a), but deeper in the intimal hyperplasia. 
Numerous smooth muscle cells (S) with predominately contractile filaments and li tle rough endoplasmic reticulum (arrows) are found. 
Original magnification x 3000. 
(c) Transmission electron micrograph of a L-NAME-treated vein graft showing an intact e dothelial ce l (E). Numerous smooth muscle 
cells (S) of the synthetic phenotype with clearly defined abundant rough endoplasmic reticulum are seen (arrows). Large nucleoli 
(arrowheads) are seen in several smooth muscle cells. Original magnification x 3900. 
Physiological responses 
There were no changes in the sensitivities (pD2) to 
norepinephrine, serotonin and bradykinin following 
treatment with SNAP or L-NAME compared to gel 
coated grafts (Table 2). The E .... generated by the 
locally treated SNAP treated grafts in response to 
norepinephrine and serotonin were increased com- 
pared to gel controls while that to bradykinin was 
decreased (Table 3). The Ema x generated by the locally 
treated L-NAME treated grafts in response to nor- 
epinephrine and bradykinin were increased, and those 
to serotonin were decreased compared to controls 
(Table 3). No precontracted control vein grafts relaxed 
in response to the receptor: mediated, endothel ium 
dependent relaxing agent, acetylcholine. The gel 
coated vein grafts relaxed to acetylcholine (16 of 24 
rings) with a maximal relaxation of 59 ± 7% (Table 2). 
All rings in the local SNAP treated vein grafts showed 
relaxation in response to acetylcholine (maximal re- 
laxation: 50 + 6%). Similarly, all rings in the local L- 
NAME treated vein grafts showed relaxation in re- 
sponse to acetylcholine (maximal relaxation 42 ± 6%). 
The sensitivity (pD2) of the response in the gel treated 
groups alone was significantly greater than either the 
SNAP or L-NAME treated vein grafts. In response to 
sodium nitroprusside (a non-receptor mediated, non- 
endothel ium dependent relaxing agent), there was no 
significant change in the sensitivities of the control, 
gel coated and L-NAME treated vein grafts but there 
was a marked increase in sensitivity of the SNAP 
treated vein grafts (Table 2), with maximal relaxations 
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Table 2. Sensitivity of physiological responses. 
Control (n=4) Gel control (n-4) SNAP (n=4) L-NAME (n=4) p-value 
Norepinephrine 6.09 ± 0.09 6.04 _+ 0.06 6.02 ± 0.06 6.01 ± 0.06 ns 
Bradykinin 5.47 ± 0.05 5.71 ± 0.06 5.60 ± 0.08 5.66 ± 0.08 ns 
Serotonin 6.34 ± 0.15 6.06 ± 0.07 6.32 ± 0.07 6.17 ± 0.10 ns 
Acetylcholine No response 7.25 ± 0.41" 6.32 ± 0.12 6.28 ± 0.17 0.03 
Sodium nitroprusside 6.04±0.22 6.11 ±0.17t 6.96±0.12 6.47±0.18 0.01 
Sensitivity of the contractile and relaxant responses for the control, gel encased and S-nitroso-N-acetylpenicillamine (SNAP) and nitro-L- 
arginine methyl ester (L-NAME) treated grafts. The ECs0 value, the concentration for the half maximal response, for each agonist in each 
ring was calculated by logistic analysis and is expressed as the pD2 which is defined as -logl0[ECs0]. All data are mean ± standard error 
of the mean (S.mM.) and statistical differences between groups were tested by ANOVA with post hoc Tukey-Kramer multiple comparison 
tests (p<0.05 vs. control and p<0.01 vs. gel control). 
* Eight of 24 rings failed to relax. 
Table 3. Maximal physiological responses. 
Control (n =4) Gel control (n =4) SNAP (n =4) L-NAME (n =4) p-value 
Norepinephrine 1.62 ± 0.36 1.23 ± 0.11 1.94 ± 0.21 2.40 ± 0.41 0.06 
Bradykinin 0.38 ± 0.21 0.65 ± 0.11 0.43 i 0.07 1.06 ± 0.22* 0.03 
Serotonin 0.41 ± 0.08 0.78 ± 0.13 1.93 ± 0.27t 0.46 ± 0.16 0.001 
Maximal contractile responses for the control, gel encased and S-nitroso-N-acetylpenicillamine (SNAP) and nitro-L-arginine methyl ester 
(L-NAME) treated grafts. Em~x (the maximal response xpressed as a ratio of the contraction to 60 mM KC1). All data are meanis.~.M. 
Statistical differences between groups were tested by ANOVA with post hoc Tukey-Kramer multiple comparison tests (*p<0.05 vs. control 
and tp<0.001 vs. control, gel control and L-NAME). 
of 91 ± 2%, 94 _+ 6%, 97 + 2%, and 99 ± 1%, respectively, 
for each of the groups. 
In vitro (H ~) thymidine incorporation and ceil 
proliferation 
SNAP and L -NAME both inhibited the in vitro in- 
corporat ion of (H 3) thymid ine into the DNA of serum- 
st imulated cultured rabbit aortic smooth  muscle cells 
(Fig. 4a). The ICs0 for SNAP was 90 gM and for L- 
NAME 2 mM. Incubat ion of smooth muscle cell cul- 
tures with increasing concentrat ions of S-nitroso-N- 
acetylpenici l lamine (10 SM, 5x10  5M, 10 4M, 
5 x ]0-4M,  10-3M) inhibited in a concentrat ion de- 
pendent  manner  the in vitro cellular prol i feration in 
response to serum st imulat ion (Fig. 4b). Incubat ion of 
smooth muscle cell cultures with increasing con- 
centrations of nitro-L-arginine methyl  ester 
(5 x 10-4M, 10 3M, 5 x 10-3M, 10-2M) produced  a 
triphasic pattern in the in vitro cellular prol i feration 
in response to serum st imulat ion (Fig. 4c). At the lowest 
concentrat ions (5 x 10 .4 M), there was an increase in 
cell proliferation. There was no significant change 
in cell prol i feration at 10-3M, while at 10-2M and 
5 x 10-3M there was inhibit ion of cell prol i feration 
(Fig. 4c). 
In vitro protein and collagen synthesis 
Incubat ion of smooth  muscle cell cultures with in- 
creasing concentrat ion of S-nitroso-N-acetylpenici l la- 
mine (0.0 mM, 0.4 mM, 0.8 mM and 1.2 mM) did not 
inhibit the in vitro protein and collagen synthesis (Figs 
4d and 4e). Cycloheximide (1 gM) resulted in an 80% 
decrease in both protein and col lagen synthesis (Figs 
4d and 4e). 
Discussion 
Endothel ial  cells regulate the structure of the vessel 
wall  by  produc ing both growth-promot ing  and 
growth- inhib i tory factors, and by  modulat ing  the com- 
posit ion of the extracellular matrix. Changes in these 
endothel ial  cell functions and structure play a central 
role in the pathophys io logy  of the major cardiovascular 
diseases (atherosclerosis, hypertens ion and diabetes) 
and in particular, of the clinical phenomena of intimal 
hyperplas ia nd restenosis. 22Previous work  has shown 
that within 1 day  fol lowing insertion of the vein as a 
vein graft into the arterial circulation, NO-mediated,  
endothel ium dependent  relaxation is lost. After 7 days, 
non-receptor mediated relaxation returns but  the vein 
graft does not recover receptor mediated relaxation. 23 
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Fig. 4. (a) The response of in vitro (3H)-thymidine incorporation i to the DNA of cultured rabbit vascular smooth muscle ceils in the 
presence of SNAP (©) and L-NAME (11) at concentrations of 10-s-10-2M. Values are the mean±s.e.M, per cent of the control for six 
experiments. The ICs0 for SNAP is 90 p.M and for L-NAME 2 raM. The IC2s and IC75 for SNAP are 17 pM and 500 pM, respectively, and 
IC25 and IC75 for L-NAME are 0.4 mM and 13 raM, respectively. 
(b) The dose dependent inhibition of the in vitro proliferation ofcultured rabbit vascular smooth muscle cells by SNAP at five concentrations: 
10-5M (Q), 5 x 10-5M ([]), 10 4M (11), 5 x 10-3M (A) and 10 3M (A) compared to control (©). Values are the mean_+ S.E.M. of cell 
counts ( x 103) per ml for six experiments. 
(c) The dose dependent inhibition of the in vitro proliferation of cultured rabbit vascular smooth muscle cells by L-NAME at four 
concentrations: 5 x 10-4M (O), 10-3M ([Z), 5 x 10-BM (m), 10 2M (A) compared to control (C)). Values are the mean_+s.E.M, of cell 
counts ( x 103) per ml for six experiments. 
(d) The relative rates of total protein synthesis as determined by [SH]-leucine incorporation i to cultured rabbit vascular smooth muscle 
cells in the presence of S-nitroso-N-acetylpenicillamine (SNAP; 0.1 mM, 0.4 mM, 0.5 mM, 0.8 raM, i mM and 1.2 raM) did not inhibit in 
vitro protein synthesis compared to untreated controls. Cycloheximide (1~tM) resulted in an 80% decrease in protein synthesis, compared 
to control. Values are the mean_+ S.~.M. per cent of the control for three experiments. 
(e) The relative rates of total protein and collagen synthesis as determined by (3H)-proline incorporation i to cultured rabbit vascular 
smooth muscle cells treated with collagenase III and without collagenase III (protein) in the presence of S-nitroso-N-acetylpenicillamine 
(SNAP; 0.4 mM, 0.8 mM and 1.2 raM) did not inhibit in vitro protein and collagen synthesis compared to untreated controls. Cycloheximide 
(1 pM) resulted in an 80% decrease in collagen synthesis. Values are the mean _+ s.E.M, per cent of the control for three experiments. (N) 
Protein; ([]) collagen. 
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During these 7 days, smooth muscle cell proliferation 
occurs and intimal hyperplasia develops. Chronic L- 
arginine therapy reduces the development ofvein graft 
intimal hyperplasia t 28 days with preservation of 
NO mediated relaxation. 24'25 Single dose therapy of 
vein grafts by immersion for 45 min before insertion, 
with a free radical scavenger, desferrioxamine man- 
ganese, can both reduce intimal hyperplasia nd pre- 
serve NO mediated relaxation at 28 daysY 
Several studies have shown that there is a time- 
dependent accumulation and infiltration of PMNs into 
the wall of a vein graft over the first 5 days of im- 
plantation, suggesting that there may be considerable 
PMN mediated free radical injury to both the endo- 
thelial and smooth muscle cells. 2'26'27 Activated oxygen 
species can induce smooth muscle proliferation and 
proto-oncogene expression in vitro, and thus may be 
important in the initiation of intimal hyperplasia. 28
The probable importance of oxygen free radicals in 
the development of intimal hyperplasia has been dem- 
onstrated by the facts that single therapy of vein grafts 
with desferrioxamine manganese by immersion for 
45 min before insertion, can reduce intimal hyper- 
plasia, 17 while chronic therapy with the antioxidants, 
21-aminosteroid (U74389G) and methylaminochrom- 
ans (U83836E), also appeared to be as effective in 
controlling the development of intimal hyper- 
plasia. 18"29 This study demonstrates that immediate and 
short-term supplementation f NO in vein grafts using 
an NO donor results in a significant decrease in intimal 
hyperplasia. Although SNAP has not been employed 
in arterial models to date, para-arterial dministration 
of nitroglycerin, a source of NO, for 1 week has been 
shown to increase cGMP levels and to decrease medial 
smooth muscle cell proliferation after balloon injury, 
but not to have an effect on intimal smooth muscle 
cell proliferation. Despite these early effects, para- 
arterial administration ofnitroglycerin did not change 
the final development of intimal hyperplasia in this 
study. 3° In a similar study, oral molsidomine (whose 
active metabolite is SIN-l, an NO donor) given for 
48 h after carotid angioplasty significantly reduced 
intimal smooth muscle cell proliferation but did not 
change the final development of intimal hyperplasia 
at 21 days. 31 
Local short-term inhibition of NO synthase by L- 
NAME had no effect on the development of intimal 
hyperplasia in the vein grafts. Inhibition of NO syn- 
thase with L-NAME has also been shown not to alter 
the course of intimal hyperplasia in denuded arteries 23 
but it will worsen the progression of atherosclerosis 
in experimental models .  33'34 Application of L-NAME 
in a pluronic gel around a denuded carotid artery will 
increase platelet adhesion and decrease flow within 
the carotid artery over the first 5 days, which is pre- 
sumed to be due to inhibition of iNOS activity in 
the medial smooth muscle cells. 35 In this study, the 
immediate and short-term inhibition of NO synthase 
in vein grafts did not change the development of 
intimal hyperplasia. The beneficial effects of NO and 
the absence of any effects with L-NAME suggest hat 
activation of NOS, either fully or partially, is absent 
in vein grafts after insertion, which would be in keep- 
ing with previous reported functional data. 36 L-NAME 
should have increased the development of intimal 
hyperplasia if an NOS was functioning or should have 
decreased if the NO synthase was functioning but 
producing significant free radicals due to an L-arginine 
poor local environment. Neither situation occurred, 
allowing one to postulate that there is an intrinsic 
defect with the activation of NOS in the vein graft 
endothelial cells; this has been suggested by previous 
work on retrieved human vein graftsF The decrease 
in intimal hyperplasia seen with the application of an 
NO donor suggests that the presence of NO for a short 
period of time has interrupted the triggering processes 
for vein graft intimal hyperplasia. A similar phe- 
nomenon was observed with the free radical scavenger 
desferrioxamine manganese. 24'25 Preventing eneration 
of free radicals with desferrioxamine or increasing 
their degradation with NO suggest hat free radical 
production is a part of the initiation of vein graft 
intimal hyperplasia. 
The vein grafts treated with either SNAP or L- 
NAME showed no changes in sensitivities to the three 
contracile agonists tested; the maximal responses of 
the smooth muscle cells did increase, but the changes 
were not uniform. The lack of change in sensitivities 
suggests that the functional smooth muscle cell pheno- 
type present in the vein grafts is unchanged compared 
to the gel treated controls. We have noted similar 
pattern of responses in the several gel delivered ther- 
apies we have tested (antisense to c-myb, angiotensin 
II receptor antagonist). 3s'39 Chronic therapies appear to 
be more effective in modulating phenotypic hanges 
in the smooth muscle cells, which would be consistent 
with the theories that vein grafts experience continuing 
stimuli for smooth muscle cell modulation and intimal 
hyperplasia development. 4° All gel coated vein grafts 
relaxed to acetylcholine, which appears to be a factor 
of the gel as opposed to the content of the gel. In 
contrast, the response of the smooth muscle cells to 
the direct smooth muscle cell relaxing agent sodium 
nitroprusside was increased, with the vein grafts in 
the SNAP group having a greater esponse than those 
in the L-NAME group. 
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In electron microscopy there appears to have been 
a significant impact on the ultrastructure of the vein 
grafts treated with SNAP and L-NAME compared 
to the control and gel treated vein grafts. Extensive 
descriptions of the ultrastructure of the vein graft have 
been published by th i s  group.iS'22'25'29 It would appear 
that the presence of SNAP modulated the phenotypes 
of the smooth muscle cells to a predominantly con- 
tractile (mature) phenotype, whereas the presence of 
L-NAME induced a predominant synthetic (immature) 
phenotype. These ultrastructural results are not re- 
flected in the functional studies, where there was a 
lack of change in sensitivities to the contractile agonists 
used, suggesting no change in smooth muscle cell 
phenotype. In the L-NAME group both the presence 
of the synthetic phenotype (rough endoplasmic re- 
ticulum) and the conspicuous nucleoli are signs of 
heightened synthetic activity within the cells, whereas 
in the SNAP treated vessels the presence of the con- 
tractile phenotype suggests less synthetic activity. On 
the luminal surface there are more and larger stomata 
between the endothelial cells of the L-NAME group 
compared to the SNAP treated group, which may 
facilitate greater permeability of the endothelium 
present. 
The in vitro studies in this study demonstrate that 
both SNAP and L-NAME are capable of inhibiting 
DNA synthesis and cell proliferation. The IC50 for 
SNAP was 90 gM, which was 20 times less than the 
ICs0 for L-NAME (2 mM). Both concentrations are very 
high and unlikely to have been achieved in vivo and 
may suggest that SNAP did not prevent intimal 
hyperplasia by a direct effect on smooth muscle cell 
proliferation. This contention has been supported by 
other studies. Although in primary cultures, SNAP 
specifically increases the efficacy but not the potency 
of fibroblast growth factor-2 induced thymidine in- 
corporation and cell proliferation in vitro, SNAP de- 
creased mitogen-induced thymidine incorporation in 
later subcultures of smooth muscle cells. 4L42 SNAP at 
high concentrations has also been shown to produce 
dose dependent inhibition of protein and collagen 
synthesis in smooth muscle cell cultures. 19 In this study, 
SNAP at concentrations equivalent o those used in 
the gel did not inhibit protein and collagen synthesis 
in smooth muscle cell cultures. 
In conclusion, local treatment with an NO donor 
produces a significant reduction in vein graft intimal 
hyperplasia, but the addition of an NO synthase in- 
hibitor does not produce any effect. These data confirm 
the protective effect of NO in vascular injury and 
suggest hat NO synthase activity is either absent or 
reduced to a level that further inhibition in this short 
time course is not relevant o the pathophysiology of 
vein graft intimal hyperplasia. However, local ap- 
plication of an NO donor may be clinicall applicable. 
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